Sanofi and Regeneron likely to cough up royalties to end Amgen’s PCSK9 patent suit: Analyst

Tracy Staton

One of the hottest races for market share in pharma these days is between Amgen's cholesterol-fighter Repatha and Praluent, from and . They're apparently neck and neck with payers, and their script numbers aren't much different either, at least so far.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS